View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 29, 2020

Allergan’s ophthalmic solution shows near vision gains in presbyopia trials

AbbVie company Allergan has announced that the Phase III GEMINI 1 and 2 trials of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for treating presbyopia symptoms have met their primary efficacy endpoint.

AbbVie company Allergan has announced that the Phase III GEMINI 1 and 2 trials of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for treating presbyopia symptoms have met their primary efficacy endpoint.

Presbyopia is a progressive eye condition that decreases the eye’s ability to focus on near objects.

AGN-190584 is an optimised formulation of pilocarpine, a cholinergic muscarinic receptor agonist.

The drug is being analysed as a topical, once-daily drop delivered by a vehicle for the treatment of symptoms associated with presbyopia.

AGN-190584 works through dynamic pupil modulation, an effect where the iris sphincter is contracted to achieve pupil size reduction in an optimal range. Pupil size reduction will result in an increased depth of focus.

For the trials, a total of 750 patients were enrolled and randomised in a one-to-one ratio to receive AGN-190584 (pilocarpine 1.25%) or vehicle (placebo).

Subjects with presbyopia were administered with AGN-190584 bilaterally, once-daily, for 30 days.

The formulation showed significant near vision gains in both studies and in mesopic (in low light) conditions without a loss of distance vision, meeting the primary endpoint.

Most of the trials’ secondary endpoints were met, including a significant improvement in patient-reported outcomes.

The outcomes were increased vision-related reading ability and reductions in the impact of presbyopia on daily life and use of coping behaviours to manage presbyopia.

AbbVie ophthalmology vice-president, global therapeutic area head Michael Robinson said: “Our research shows that the symptoms associated with presbyopia can significantly impact people’s daily lives.

“The positive results from the GEMINI studies show the potential of this investigational optimised formulation of pilocarpine 1.25% to treat symptoms associated with presbyopia.”

The company plans to submit a New Drug Application to the US Food and Drug Administration (FDA) in the first half of next year. The results of these GEMINI trials will become the basis for the process.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU